作者
Freja Bach Kampmann, Sanne Marie Thysen, Camilla Friis Bryde Nielsen, Klaus Fuglsang Kofoed, Lars Køber, Michael Huy Cuong Pham, Allan Vaag, Niklas Rye Jørgensen, Janne Petersen, Rikke Kart Jacobsen, Line Lund Kårhus, Axel Diederichsen, Marie Frimodt-Møller, Allan Linneberg
发表日期
2023/5/1
期刊
BMJ open
卷号
13
期号
5
页码范围
e071885
出版商
British Medical Journal Publishing Group
简介
Introduction
Vitamin K has been suggested to have protective effects against progression of vascular calcification and development of cardiovascular disease (CVD). However, few well-powered randomised controlled trials have examined whether vitamin K prevents progression of vascular calcification in individuals from the general population. The aim of the InterVitaminK trial is to investigate the effects of vitamin K supplementation (menaquinone-7, MK-7) on cardiovascular, metabolic, respiratory and bone health in a general ageing population with detectable vascular calcification.
Methods and analysis
The InterVitaminK trial is a randomised, double-blinded, placebo-controlled, trial. A total of 450 men and women aged 52–82 years with detectable coronary artery calcification (CAC), but without manifest CVD, will be randomised (1:1) to receive daily MK-7 (333 µg/day) or placebo tablets for 3 years. Health …
学术搜索中的文章
FB Kampmann, SM Thysen, CFB Nielsen, KF Kofoed… - BMJ open, 2023